Related references
Note: Only part of the references are listed.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Shanshan Pei et al.
CANCER DISCOVERY (2020)
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells
Courtney L. Jones et al.
CELL STEM CELL (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
Courtney L. Jones et al.
CANCER CELL (2018)
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
Daniel A. Pollyea et al.
NATURE MEDICINE (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
Adriana Plesa et al.
WORLD JOURNAL OF STEM CELLS (2017)
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Xiaojia Niu et al.
CLINICAL CANCER RESEARCH (2016)
Acute myeloid leukaemia
Asim Khwaja et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study
Francois Vergez et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)